Answers are grounded in this paper and cite their sources.
OBJECTIVE: Oral, low-dose and ultra-low-dose continuous combined 17β-estradiol (E) plus dydrogesterone (D) reduce vasomotor symptoms (VMS) in postmenopausal women. METHODS: ) included number of hot flushes and moderate-to-severe hot flushes per day, and the proportion of women with amenorrhea. RESULTS: : 4.2 [3.6, 4.9]). A similar pattern was seen for moderate-to-severe hot flushes. The amenorrhea rate was high (79-98%) across both studies and BMI subgroups. CONCLUSION: Oral, ultra-low-dose continuous combined E0.5 mg/D2.5 mg and low-dose continuous combined E1 mg/D5 mg alleviated postmenopausal VMS compared with placebo, irrespective of BMI.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: